Synthesis of a Selective Orexin 1 Receptor Antagonist: Development of a Manufacturing Process─Part 2
In campaign 1, 75.3 kg of (S)-2-(methylamino)-1-[5-(trifluoromethyl)-2-pyrazinylamino]propane hydrochloride salt was prepared in two stages from (S)-2-(N-benzyl-N-methylamino)-1-propanamine d-tartaric acid salt. The first stage was the alkylation of 2-chloro-5-(trifluoromethyl)pyrazine. The second stage was the removal of the benzyl protecting group by hydrogenolysis. In campaign 2, 251 kg of (S)-2-(methylamino)-1-[5-(trifluoromethyl)-2-pyrazinylamino]propane hydrochloride salt was produced, this time starting from the d-mandelic acid salt of (S)-2-(N-benzyl-N-methylamino)-1-propanamine. Investigations into alternative routes of synthesis for (S)-2-(methylamino)-1-[5-(trifluoromethyl)-2-pyrazinylamino]propane identified two options: one via (5R)-5-methyl-3-[5-(trifluoromethyl)pyrazin-2-yl]-1,2λ6,3-oxathiazolidin-2,2-dione and the other via (S)-2-(N-benzyloxycarbonyl-N-methylamino)propionitrile.
Authors
- Paul Leong
- John S Carey (ORCID: https://orcid.org/0000-0002-3654-0063)
- Andrew Knowles
- Harrison Holmes
Institutions
- The Priory Hospital (GB)
- Lonza (Switzerland) (CH)
Publication Details
- Journal
- Organic Process Research & Development
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1021/acs.oprd.6c00297
- Citations
- 3
- Primary Topic
- Chemical Synthesis and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 3.78